Detalhe da pesquisa
1.
A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
Clin Trials
; 8(1): 5-14, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21335586
2.
Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean?
Psychiatry Res
; 170(2-3): 172-6, 2009 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-19897253
3.
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
Am J Psychiatry
; 162(8): 1535-8, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16055779
4.
Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Psychopharmacology (Berl)
; 178(4): 514-23, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15650846
5.
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Am J Psychiatry
; 161(10): 1837-47, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15465981
6.
A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment.
Am J Psychiatry
; 159(1): 96-102, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11772696
7.
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
J Clin Psychiatry
; 65(12): 1624-33, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15641867
8.
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.
Schizophr Res
; 66(2-3): 101-13, 2004 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15061242
9.
The Importance of Adequately Powered Clinical Studies: Response to Khan et al.
Am J Psychiatry
; 175(2): 188-189, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29385831
10.
Why Are Innovative Drugs Failing in Phase III?
Am J Psychiatry
; 174(9): 829-831, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28859511
11.
Communication about results of comparative effectiveness studies: a pharmaceutical industry view.
Health Aff (Millwood)
; 31(10): 2213-9, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23048099
12.
Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
J Psychiatr Res
; 44(1): 8-14, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19699488
13.
Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the future.
Int J Alzheimers Dis
; 20092009 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20798873
14.
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study.
J Clin Psychiatry
; 68(7): 1071-7, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17685744
15.
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
J Clin Psychopharmacol
; 23(6): 595-600, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14624190